Novel biomaterials for bisphosphonate delivery

Josse, Solen; Faucheux, Claude; Soueidan, Assem; Grimandi, G.; Massiot, Dominique; Alonso, Bruno; Janvier, Pascal; Laı̈b, Samia; Pilet, Paul; Gauthier, Olivier; Daculsi, Guy; Guicheux, Jérôme; Bujoli, Bruno; Bouler, Jean‐Michel

doi:10.1016/j.biomaterials.2004.05.019

Cited by 147 publications

(140 citation statements)

References 44 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…24 It was also demonstrated that calcium phosphate substrates supported controlled delivery of bisphosphonate or simvastatin molecules. [32][33][34] Other studies indicated that release of adsorbed molecules can be affected by the chemical and structural characteristics (e.g., Ca/P ratio, crystallinity, surface texture) of the calcium phosphate substrates. [35][36][37] We further investigated the ability of phenamil to induce bone regeneration in calvarial defect model well established in our previous studies.…”

Section: Discussionmentioning

confidence: 99%

Delivery of Phenamil Enhances BMP-2-Induced Osteogenic Differentiation of Adipose-Derived Stem Cells and Bone Formation in Calvarial Defects

Fan

Cui

et al. 2015

Tissue Engineering Part A

View full text Add to dashboard Cite

Bone morphogenetic proteins (BMPs) have been widely used for bone repair in the craniofacial region. However, its high dose requirement in clinical applications revealed adverse effects and inefficient bone formation, along with high cost. Here, we report a novel osteoinductive strategy to effectively complement the osteogenic activity of BMP-2 using phenamil, a small molecule that can induce osteogenic differentiation via stimulation of BMP signaling. Treatment of adipose-derived stem cells (ASCs) with BMP-2 in combination with phenamil significantly promoted the in vitro osteogenic differentiation of ASCs. The efficacy of the combination strategy of phenamil + BMP-2 was further confirmed in a mouse calvarial defect model using scaffolds consisting of poly(lactic-co-glycolic acid) and apatite layer on their surfaces designed to slowly release phenamil and BMP-2. Six weeks after implantation, the scaffolds treated with phenamil + BMP-2 significantly promoted mouse calvarial regeneration as demonstrated by micro-computerized tomography and histology, compared with the groups treated with phenamil or BMP-2 alone. Moreover, the combination treatment reduced the BMP-2 dose without compromising calvarial healing efficacy. These results suggest promising complementary therapeutic strategies for bone repair in more efficient and cost-effective manners.

show abstract

Section: Discussionmentioning

confidence: 99%

Delivery of Phenamil Enhances BMP-2-Induced Osteogenic Differentiation of Adipose-Derived Stem Cells and Bone Formation in Calvarial Defects

Fan

Cui

et al. 2015

Tissue Engineering Part A

View full text Add to dashboard Cite

show abstract

“…Bisphosphates are antiresorptive agents that have beneficial effects for the patients on preventing further bone loss, and their effects on increasing the bone mass is modest (Kwak et al, 2009, Yoshinari et al, 2002. It has been shown that bisphosphonate incorporated on to titanium implants increased bone density locally in the peri-implant region (Josse et al, 2005) with the effect of the antiresorptive drug limited to the vicinity of the implant. Experimental in vivo studies have demonstrated the absence of negative effects, but only a slight increase in dental implant osseointegration .…”

Section: Bisphosphonatesmentioning

confidence: 99%

Dental Implant Surface Enhancement and Osseointegration

Anil¹,

Anand²,

Alghamdi³

et al. 2011

Implant Dentistry - A Rapidly Evolving Practice

View full text Add to dashboard Cite

“…An alternative for this treatment is employing implantable drug delivery vectors to release the pharmaceutical agent exactly in the place where it is specifically needed. This technology has been explored using polymeric microspheres (13,14), organic-inorganic composites (15), and calcium phosphates (16,17). It is also possible to employ the abovementioned ordered mesoporous ceramics to exploit all the advantages that these systems present over traditional systems (18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

Anti-Osteoporotic Drug Release from Ordered Mesoporous Bioceramics: Experiments and Modeling

et al. 2011

View full text Add to dashboard Cite

Abstract. The release of a potent bone-resorption inhibitor such as zoledronate from a versatile drug delivery system such as SBA 15 has been modeled. The initial and boundary conditions have been defined, together with the system parameters, including the determination of equilibrium and transport parameters. Additionally, the experimental model of the same system has been observed to validate the prediction here developed. This approach represents a powerful tool for the designing of mesoporous implantable drug delivery systems because their release kinetics can be predicted in advance, and this leads to a considerable time and resources saving.

show abstract

Novel biomaterials for bisphosphonate delivery

Cited by 147 publications

References 44 publications

Delivery of Phenamil Enhances BMP-2-Induced Osteogenic Differentiation of Adipose-Derived Stem Cells and Bone Formation in Calvarial Defects

Delivery of Phenamil Enhances BMP-2-Induced Osteogenic Differentiation of Adipose-Derived Stem Cells and Bone Formation in Calvarial Defects

Dental Implant Surface Enhancement and Osseointegration

Anti-Osteoporotic Drug Release from Ordered Mesoporous Bioceramics: Experiments and Modeling

Contact Info

Product

Resources

About